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Abstract.  Shortly after birth, cardiac myocytes lose 
the ability to divide, and, in adult animals, heart mus- 
cle grows by a process of cellular hypertrophy where 
each individual cell gets larger. We have previously 
shown that activated Ras protein can induce markers 
of the hypertrophic phenotype, including atrial natri- 
uretic factor (ANF) expression and organization of 
contractile proteins, and that Ras is at least partially 
required for the hypertrophic effect of phenylephrine. 
In the present study, we examine the requirement for 
the mitogen-activated protein kinases (MAP kinases) 
in the hypertrophic response induced by phenyleph- 
fine. We find that phenylephrine treatment results in 
the activation of the MAP kinases and that this activ- 
ity is required for transactivation of the fos, ANF, and 
MLH promoters. However, inhibition of MAP ki- 
nases does not prevent phenylephrine-induced organi- 
zation of actin. These results suggest that the signal 
transduction pathways leading to different hypertrophic 
responses diverge upstream of the MAP kinases but 
possibly downstream of Ras. 
T 
HE  molecular mechanisms which regulate cardiac 
muscle cell hypertrophy are unclear; however, it is 
becoming apparent that activation of various signaling 
molecules that are known to be involved in the growth and 
differentiation  of other cell types is also important in the 
hypertrophic response.  Culture systems using neonatal rat 
ventricular cardiomyocytes  have been developed (Simpson, 
1983) which respond to treatment with various agonists by 
displaying many features of the hypertrophic response (for 
review see Chien et al.,  1991). Both heterotfimeric G pro- 
tein-coupled  agonists  (e.g.,  phenylephrine  [Lee  et  al., 
1988], Endothelin-1 [Ito et al., 1991; Shubeita et al., 1990] 
and Angiotensin I/[Sadoshima and lzumo, 1993b]), tyrosine 
kinase-coupled agonists (e.g., fibroblast growth factor [Par- 
ker et al.,  1990]), phorbol esters (Dunnmon et al.,  1990), 
and mechanical stretch  (Komuro  et al.,  1991) have been 
shown to induce the hypertrophic phenotype. The hyper- 
trophic response in neonatal ventricular myocytes is charac- 
terized by a series of phenotypic changes. These changes in- 
clude (a) an increase in myocyte size; (b) increased protein 
synthesis; (c) activation of the expression of specific genes 
including  embryonic markers like atrial  natriuretic factor 
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(ANF)  m  (Knowlton  et al.,  1991), contractile proteins like 
myosin light chain-2  (MLC-2)  (Lee et al.,  1988), and im- 
mediate early genes including c-fos (Izumo et al., 1988); and 
(d) increased organization of contractile proteins into sarco- 
meric units (Iwaki et al.,  1990). 
The mitogen-activated protein (MAP) kinases are ubiqui- 
tously expressed serine/threonine protein kinases which are 
activated in response to diverse stimuli (Boulton et al., 1991; 
Cobb et al., 1991; Thomas,  1992), and they are thought to 
be critical components in the signal transduction pathways 
which regulate cell growth and differentiation. MAP kinase 
activation occurs as a result of phosphorylation on threonine 
and tyrosine residues (Payne et al., 1991) by a MAP kinase 
kinase (MEK) (Ahn et al., 1992). MEKs are themselves acti- 
vated by phosphorylation indicating the existence of a MEK 
kinase activity in the cell (Gomez and Cohen, 1991). A num- 
ber of different ldnases have been shown to function as MEK 
kinases  including  Raf-1 (Dent et al.,  1992; Howe et al., 
1992; Kyriakis et al., 1992), MEK Kinase (Lange-Carter et 
al., 1993), and Mos (Posada et al., 1993). It has been sug- 
gested that the MAP kinases may represent a convergence 
point where diverse signaling pathways are brought together 
(Lange-Carter et al.,  1993). 
Recent  work  suggests  that  treatments  which result  in 
1. Abbreviations used in this paper:  ANE atrial natriuretic factor; 2AP, 
2-amino purine; MAE mitogen-activated  protein; MBP, myelin basic pro- 
tein; MEK, MAP kinase kinase; MLC-2, myosin light chain-2; TPA, phor- 
bol 12-myristate  13-acetate;  6TG, 6-thio guanine. 
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1993a;  Yamazaki et al.,  1993;  Bogoyevitch et al.,  1994). 
However, a correlation between MAP kinase activation and 
the hypertrophic  response does not necessarily mean that 
MAP kinase activity is actually  important for hypertrophy. 
We have attempted to address this question by studying the 
requirement  for  MAP  kinase  activity  for  two  different 
phenotypes associated with cardiac  myocyte hypertrophy, 
activation of gene expression and organization  of actin into 
contractile  units. In this report, we demonstrate that phenyl- 
ephrine  treatment  causes MAP kinase activation  in cardiac 
myocytes and that this  activation  is required for transcrip- 
tional  activation  but not for the organization  of actin  into 
contractile  units. Thus the signal transduction  pathway acti- 
vated  by phenylephrine  separates above the MAP kinases 
leading  to different hypertrophic  phenotypes. 
Materials and Methods 
Cell Culture 
Tissue  culture  media,  phenylephrine,  phorbol  12-myristate  13-acetate 
(TPA), 2-amino purine (2AP), and 6-thio guanine (6TG) were from Sigma 
Chem.  Co.  (St.  Louis,  MO),  serum  was  supplied  by  GIBCO-BRL 
(Gaithersburg,  MD). Neonatal rat ventricular myocytes  were isolated by 
five  20-rain  rounds  of collagenase/pancreatin digestion (95  U/ml  col- 
lagenase,  0.6 mg/ml pancreatln, GIBCO-BRL) in a buffer containing 116 
raM NaCI,  20 mM Hepes,  1 mM NaH2PO+, 5.5 mM glucose,  5.4 mM 
KCI, 0.5 raM MgSO+, pH 7.35. The cells were pelleted by low speed cen- 
trifugation and suspended in plating media (4:1, DMEM:Media 199 con- 
taining 10% horse serum and 5% FBS).  The isolated cells,  a mixture of 
myocytes  and non-myocytes  (mostly fibrohlasts)  were plated onto an un- 
treated tissue culture flask for two 45-min incubations. Non-myocytes  ad- 
hered to the flask so that the remaining unattached cells were '~90% myo- 
cytes  as  determined  by  myosin  staining,  morphology,  and  beating. 
Non-myocyte  cultures were passaged  twice to remove any contaminating 
myocytes.  For biochemical analysis,  106 cells were plated overnight onto 
6-cm gelatin-coated dishes, for transfection experiments,  5  x  105 cells 
were plated onto 3.5-cm  dishes while for immunofluorescence  analysis, 
5  x  105 cells were plated onto NUNC chamber slides (Naperville,  IL) 
(culture area 45 mmx  21 mm). After plating for 16 h, the media was 
changed to serum-free media (4:1, DMEM:I99) for 24-36 h before treat- 
ment as required. 
MAP Kinase Activation 
Cultured cells were treated with TPA (1 I~M), serum (10% FBS), or phenyl- 
ephrine (100/tM) as described for various times.  The cells were washed 
in PBS and lysed in a buffer containing 50 mM TRIS pH 7.4, 1 mM EDTA, 
1 raM EGTA, 50 mM NaF,  1 mM Na orthovanadate,  1% Triton X-100, 
0.5 % NP-40 plus 1 mM PMSF, 20 t+g/ml leupeptin and 20/zg/rnl pepstatin. 
For direct Western analysis of the apparent mobility of the kinases on SDS 
gels, the protein samples were boiled in Laemmli sample buffer and sepa- 
rated on 8 % polyacrylamide gels. After transfer to nitrocellulose,  the filters 
were blocked in 4% wt/vol non-fat milk (Carnation) in PBS, 0.1% wt/vol 
Tween 20 and probed with anti-Erk antibody (Santa Cruz Bioteclmology 
Inc., Santa Cruz, CA, SC-94) diluted 1:2,000 in the blocking solution. Af- 
ter washing, the filter was incubated with diluted (1:5,000) HRP-anti-rabbit 
antibody and detected by ECL as directed by the manufacturer (Amersham 
Corp., Arlington Heights, IL). For anti-phosphotyrosine immunoprecipita- 
tion, the protein extract was incubated with agarose-conjugated  anti p-Tyr 
(Santa Cruz, SC-20A) for 4 h at 4°C, washed with cold lysis buffer, and 
analyzed by gel electrophoresis and Western blotting as before.  For the IP 
kinase assay, the protein extract was incubated with anti-Erk antibody, and 
then with Protein A/G PLUS Agarose (Santa Cruz, SC-2003).  After wash- 
ing with lysis buffer, the pellets were washed in kinase buffer (20 mM TRIS, 
pH 8, 10 mM MgC12, 1 mM DTT) and suspended in kinase buffer plus 50 
~M ATP supplemented with 10 #Ci  [32p]ATP (ICN Biomedicals,  Inc., 
Costa Mesa, CA) and 2 ~g myelin basic protein (Signm Chem. Co.). The 
kinase reaction was allowed to proceed for 10 rain at room temperature and 
stopped by adding Laemmli sample buffer and boiling. The labeled protein 
was separated on gels, stained, and the myelin basic protein (MBP) was ex- 
cised and counted by liquid scintillation counting or exposed to X-ray film. 
Ribonuclease Mapping and Northern Analysis 
FOr RNase mapping analysis, antisense riboprobes were generated for ANF 
and UlsnRNA. Labeling was achieved by including [o~32p]CTP (ICN Bio- 
medicals,  Inc.) in the reaction mix. All reagents for the ribonuclease map- 
ping were from Promega Corp.  (Madison, WI) and used as described by 
the manufacturer.  For Northern analysis of MLC-2 andfos gene expression, 
RNA samples were separated on formaldehyde  containing agerose gels, 
transferred  to nitrocellulose,  and probed with random-primed probes gener- 
ated from isolated cDNA fragments using standard methods.  Reagents for 
probe generation were from Stratagene (La Jolla, CA) and used as recom- 
mended by the manufacturer. 
Transfection Analysis 
All transfections were performed in triplicate in 3.5-cm dishes. Plasmids 
for transfection were purified by alkaline lysis followed by polyethylene gly- 
col  precipitation.  Transfections  were  performed  by  calcium phosphate 
precipitation as previously  described (Knowltun et al.,  1991; Thorburn et 
al.,  1993).  The ANF-inciferase plasmid contains a  3-kb promoter frag- 
ment, the MLC-2 luciferase plasmid contains a 2.7-kb promoter fragment 
while thefosCAT plasmid contains a 750-bp fragment. For transfection ex- 
periments using purine inhibitors (see Fig. 3 a), 1 ~g CMV/SGal plasmid 
and 3 ~g ANF-luciferase plasmid were used per dish. After transfection, 
the cells were treated with the inhibitors as required for one hour, and then 
phenylephrine was added to 100 ~M to the relevant dishes. 
For the experiments using the dominant inhibitor Erkl mutant (see Figs. 
3 b and 4), transfections were performed using 1 Cg ANF-luciferase, MLC-2 
luciferase orfosCAT; 0.7 ~tg CMV/SGal or SV4OBGal and 3/~g pCEP4 (In- 
vitrogen)  or  pCEP4K71RErkl,  pCEP4K71RErkl  was  constructed  and 
generously supplied  by Dr.  T.  Geppert, Dallas,  TX. fosCAT-transfected 
cells  were  harvested  after  20  h,  while  ANF-hiciferase  and  MLC-2 
luciferase-transfected  cells were harvested after 48 h and luciferase,  CAT, 
and BGal activities determined. The luciferase or CAT values were divided 
by the/~Gal values to normalize for differences in the transfection eflicien- 
cies. All transfection data is presented as the mean +  SD from three dishes 
of cells per sample. The data shown in each figure is from a single represen- 
tative experiment, similar results were obtained in at least three experiments 
using different preparations of cells and plasmids. 
lmmunofluorescence Analysis 
Cells were cultured on plastic chamber slides (Nunc). For analysis of the 
effect of pharmacological inhibitors of MAP kinases on actin organization, 
cells were treated with 2AP (10 raM), and then phenylephrine (100/tM) as 
required. The cells were maintained for 48 h before fixation.  Cells were 
washed with PBS, fixed with 3.6% formaldehyde  in PBS, lysed with 0.3% 
Triton X-100 in PBS and blocked in 10% goat serum in PBS plus 0.1% 
Tween 20. Then stained with FITC-conjugated  phalloidin (Sigma Chem. 
Co., 40/zg/ml in PBS, 0.5% NP-40, 2 mg/ml BSA), the cells were washed 
in PBS, 0.1% Tween 20 and mounted for fluorescence  microscopy. 
For analysis of the effect of expression of the dominant negative Erkl on 
actin organization,  cells  on chamber slides were  either transfected or 
microinjected with the dominant negative  K71RErkl  expression plasmid 
plus an RSV-luciferase plasmid. Control transfections  with the wild-type 
pCEP4Erld were also performed. 3 ~,g of the Erkl expression vectors and 
0.7 ~g of the RSV-luciferase  plasmid were used in each chamber slide. 
Transfections were performed as described above, phenylephrine  was added 
after 24 h. Nuclear microinjection of expression plasmids was performed 
as previously described (Thorburn et al., 1993) using 0.4/zg/#l pCEIMK71 
and 0.2/zg/t~l RSV-luciferase.  Cells were incubated for 1 h after injection 
to allow expression (Alberts et al., 1993), and then treated with phenyleph- 
rine for 48  h,  fixed,  and stained for luciferase and actin.  To  identify 
luciferase-expressing  cells, a  rabbit anti-luciferase antibody followed by 
Texas red anti-rabbit was used, and then actin was stained as described 
above with FITC-phalloidin.  FITC and Texas red fluorescence was detected 
using a Zeiss Axiophot fluorescence  microscope (40x or 63x objectives) 
and photographed with Kodak TMAX 400 film pushed to 800 ASA. 
Results 
The  o~-adrenergic agonist  phenylephrine  induces  the hy- 
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through a pathway which is partially dependent on Ras func- 
tion (Thorburn et al.,  1993). Since it is known that activated 
Ras  can  activate  MAP  kinases  (Leevers  and  Marshall, 
1992),  we first examined whether these kinases were acti- 
vated after phenylephrine treatment. Activation of MAP ki- 
nases Erkl and Erk2 is associated with phosphorylation on 
threonine  and  tyrosine residues  (Payne et al.,  1991),  and 
results  in  reduced  mobility  of the  proteins  in  SDS-poly- 
acrylamide gels. Fig.  1 a  shows that both phenylephrine and 
the phorbol ester TPA, induce a rapid change in the mobility 
of both Erkl  and Erk2.  Furthermore,  phenylephrine treat- 
ment increases the phosphotyrosine content of both Erkl and 
Erk2 (Fig. 1 b). To confirm that these kinases were activated 
by phenylephrine  treatment,  we immunoprecipitated  Erks 
and performed an in vitro kinase assay using MBP as a sub- 
strate. Fig.  1 c confirms that the kinases are indeed activated 
by phenylephrine treatment and that this activation persists 
for  at  least  twenty  minutes  before  starting  to  diminish. 
Phenylephrine-induced activation of Erkl  and Erk2 is spe- 
cific to  the  cardiac myocytes since  non-myocytes purified 
from the same hearts did not show any MAP kinase activa- 
tion in response to phenylephrine,  although the kinases in 
these cells were activated by treatment with TPA (Fig.  1 d). 
Downregulation of protein kinase C (PKC) by chronic treat- 
ment with TPA prevents activation of these kinases by either 
TPA or phenylephrine but not by serum (Fig. 1 e) suggesting 
that activation of PKC by phenylephrine may be important 
in this response. 
To determine whether the kinase activation observed was 
necessary for the hypertrophic response, we performed a se- 
ries of experiments designed to examine the effects of inhibi- 
tion  of these  kinases.  The nucleotide  analogues  2AP and 
6TG have been shown to inhibit the MAP kinases and to pre- 
vent the differentiation of PC12  cells in response to nerve 
growth factor (Qiu and Green 1992;  Volonte et al.,  1989). 
Fig. 2 a demonstrates that pretreatment of myocytes with ei- 
ther 2AP or 6TG results in a  significant inhibition of MBP 
kinase activity, indicating that the inhibitors work in cardiac 
myocytes as they do in PC12 cells (Qiu and Green,  1992). 
To determine whether this inhibition had any effect on the 
changes  in  the pattern of gene expression associated with 
hypertrophy, we performed experiments to measure the lev- 
els of specific mRNAs whose expression is known to be up- 
regulated in phenylephrine-induced hypertrophy. Increased 
expression of the c-fos,  ANF, and MLC-2 genes was moni- 
tored as examples of the various classes of genes (immediate 
early, embryonic, and contractile protein genes) whose ex- 
pression is increased in hypertrophy. Fig. 2 b shows the re- 
suit. Phenylephrine treatment for 24 h causes an increase in 
the amount of ANF, MLC-2, and c-fos mRNA which is in- 
hibited if the cells are preincubated with 2AP or 6TG. No 
effect on the amount of U1 snRNA or ribosomal RNAs which 
were used as loading controls was observed. 
To confirm this  finding,  and  to  determine  whether  the 
effect of the inhibitors  was actually due to decreased pro- 
moter activity, a transient transfection experiment was per- 
formed in which the activity of an ANF promoter-luciferase 
plasmid was determined in the presence and absence of the 
inhibitors.  Fig.  3  a  shows that treatment of the  cells with 
phenylephrine for 48 h results in a  significant activation of 
the ANF promoter as previously shown (Knowlton et al., 
Figure  1.  Activation of Erkl and Erk2 by phenylephrine  (PE) in 
neonatal  rat cardiomyocytes.  (a) Cultured  myocytes were treated 
with 100/~M phenylephrine or 1/~M TPA. After 0, 5,  10, 20, or 
40 rain cells were harvested and the protein samples obtained were 
separated  on SDS-polyacrylamide  gels and Western blotted.  The 
resulting blot was probed with an antibody which recognizes Erkl 
and Erk2 indicating that both TPA and phenylephrine  treatment 
retards the mobility of these proteins.  (b) Phenylephrine-treated 
cells  were  harvested  and  the  proteins  immunoprecipitated  with 
anti-phosphotyrosine,  and  then  separated  and  Western  blotted 
using  the anti-Erk  antibody,  indicating  that phenylephrine  treat- 
ment results  in increased  tyrosine  phosphorylation  of Erld  and 
Erk2.  (c)  Proteins  from phenylephrine-treated  cells  were  har- 
vested,  immunoprecipitated  with the anti-Erk  antibody, and used 
in an in vitro assay using myelin basic protein (MBP) as a substrate. 
After separation  of the labeled protein  on a gel,  the band corre- 
sponding to MBP was excised and counted indicating that there is 
an increase in Erk kinase activity after phenylephrine  treatment. 
(d) Non-myocytes (mostly fibroblasts) were purified from the cul- 
tures and treated with phenylephrine or TPA as before. After sepa- 
ration and Western blotting,  the mobility  of the Erks was deter- 
mined, showing that phenylephrine does not induce Eric activation 
of non-myocytes cardiac  cells.  (e)  PKC  was  downregulated  by 
chronic treatment with 1/~M TPA for 24 h (Shubeita et al., 1992). 
After treatment with TPA, phenylephrine or 10% FBS, the mobility 
of the Erks on SDS gels was determined by Western blotting as be- 
fore, showing that PKC dowm'egulation prevents TPA and phenyl- 
ephrine-induced  Erk activation but not serum-induced  activation. 
1991).  However, if the cells were also treated with either 
2AP or 6TG, this transactivation was abolished. The inhibi- 
tors had no apparent effect on the basal level of ANF pro- 
moter activity (data not shown). 
While the purine analogs inhibit the MAP kinases,  they 
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phenylephrine (PE)-induced transactivation  of gene expression.  (a) 
Cardiac myocytes in serum-free media were treated  as described 
with 10 mM 2AP or 0.5 mM 6TG (Sigma Chem. Co.) for 1 h, and 
then with 100/~M phenylephrine to induce MAP ldnase activity. 
After ten minutes,  the cells were harvested and the MAP ldnase ac- 
tivity towards  MBP determined by the IP kinase assay. Labeled 
MBP was separated on a gel which was dried and exposed to film 
indicating  that,  as expected  (Qiu and Green,  1992),  these treat- 
ments inhibit MAP kinases.  (b) Cells were treated with the inhibi- 
tors and phenylephrine,  and then harvested for RNA analysis.  For 
analysis  of c-fos expression,  cells were harvested after one hour 
while for analysis  of MLC-2 and ANF, they were harvested after 
24 h. For measurement ofANF mRNA, ribonuclease mapping was 
performed using antisense  probes against ANF 'and U1 snRNA as 
a loading control. For measurement offos and MLC-2 RNA levels, 
Northern blots were probed with random primed probes made from 
isolatedfos or MLC-2 cDNAs. Equal loading of  the gels for North- 
ern analysis  was confirmed by staining  the ribosomal RNA with 
ethidium  bromide. 
are not specific for these kinases and it is possible that the 
effect of gene expression is actually due to other effects of 
the inhibitors.  To address this problem, we performed tran- 
sient transfection experiments using a mutant Erkl molecule 
(K71RErkl) which acts as a dominant inhibitor.  This mole- 
cule is mutated at the ATP-binding site resulting in a  non- 
functional kinase which has been shown to be a  dominant 
negatiye inhibitor capable of preventing Ras-induced activa- 
tion of the TPA response element (Frost et al.,  1994).  We 
do not know the mechanism of action of the kinase deficient 
mutant in these experiments.  Expression of the correspond- 
Figure 3. Inhibition of MAP kinase activity prevents phenylephrine 
(PE)-induced activation of the ANF promoter.  (a) Transient trans- 
fections  were  performed  using  ANF-luciferase and  CMV-/SGal 
plasmids.  After transfection,  cells were treated  with 10 mM 2AP 
or 0.5 mM 6TG for one hour as required,  and then treated with 100 
t~M phenylephrine (PE). 48 h later cells were harvested and lucifer- 
ase and BGal enzyme activities determined.  The relative luciferase 
levels (normalized to 13Gal) were plotted. Each bar represents  the 
mean  (+SD)  from three  separate  dishes  of cells.  (b)  Transient 
transfeetion  analysis was carried out using ANF-luciferase, CMV 
BGal,  and either pCEP4 (Invitrogen)  or pCEP4 K71RErkl  (con- 
strutted and generously provided by Dr. T. Geppert, University of 
Texas,  Dallas,  TX).  After treatment  with phenylephrine as de- 
scribed,  relative  luciferase  levels  were determined,  showing  that 
the mutant Erkl prevents phenylephrine-induced  transactivation  of 
the ANF promoter. 
ing kinase-deficient Erk2 molecule (K52RErk2) in CV1 cells 
inhibits basal and EGF-induced MAP kinase activity (Son- 
tag et al.,  1993) while a  different dominant negative Erkl 
molecule mutated in the activation phosphorylation sites has 
been shown to prevent activation of endogenous MAP ki- 
nases and has been used to show a requirement for MAP ki- 
nase activation for growth of fibroblasts (Pages et al., 1993). 
An  ATP-binding  site,  kinase-deficient  dominant  negative 
Raf-1 molecule, has been shown to prevent activation of the 
endogenous Raf-1 kinase in Xenopus oocytes (MacNichol et 
al.,  1993). Taken together, these data would suggest that the 
most likely mode of action is that the mutant competes for 
MAP  kinase  activators  thus  preventing  activation  of the 
MAP kinases. 
Transfections  were performed  using  the ANF-luciferase 
plasmid plus the mutant Erkl or the parental expression vec- 
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Figure 4. K71R Erkl prevents phenylephrine-induced  transactiva- 
tion of tbefos and MLC-2 promoters. Transient transfection analy- 
sis  was carried out  using fosCAT  (a) or MLC-2-1uciferase (b), 
SV40/3Gal and either pCEP4 or pCEP4 K71RErkl plasmids. After 
treatment with phenylephrine, relative CAT and luciferase activities 
were determined,  showing that the mutant Erkl inhibits phenyleph- 
rine-induced  transactivation  of the fos and MLC-2 promoters. 
tor  (pCEP4),  and  the  cells  were  treated  with  or  without 
phenylephrine.  Fig. 3 b  shows that phenylephrine activated 
the ANF promoter when the parental vector was cotrans- 
fected but that this transactivation is abolished by cotransfec- 
tion with the mutant Erk plasmid.  No significant effect on 
basal ANF promoter activity was found.  This result there- 
fore confirms that MAP kinase activity is important for the 
activation of the ANF promoter by phenylephrine treatment. 
Similar transfection experiments were also performed to de- 
termine whether MAP kinase activity was required for acti- 
vation of the fos and MLC-2 promoters by phenylephrine. 
Fig.  4  shows that expression of the mutant Erkl  molecule 
also inhibits phenylephrine-induced transaetivation of these 
promoters. 
The data outlined above suggests that MAP kinase activity 
is required for at least some hypertrophic responses to phen- 
ylephrine. We were therefore interested in looking at differ- 
ent hypertrophic phenotypes. In the neonatal rat cells, hyper- 
trophy is associated with increased organization of contractile 
proteins such as MLC-2 (Iwaki et al.,  1990) and actin. This 
effect can be conveniently monitored by staining filamentous 
actin with fluorescently labeled phalloidin. Fig. 5 shows an 
experiment where cells were treated with or without phenyl- 
ephrine in the presence of 2AE  Panel a  shows cells main- 
tained in serum-free medium with no phenylephrine. These 
Figure  5.  MAP  kinase  inhibition  by  2AP  does  not  prevent 
phenylephrine-induced  organization  of actin.  Cells  were  plated 
onto plastic  chamber slides,  maintained  in serum-free  medium, 
treated with 10 mM 2AP as required, and then with phenylephrine. 
After 48 h, the ceils were washed, fixed, and stained with FITC- 
conjugated phalloidin to visualize  the actin fibers, a  shows cells 
which were kept in serum-free medium and have not hypertrophied, 
they are small and the actin is not organized into contractile units. 
b shows phenylephrine-treated  cells, which show the morphology 
associated with hypertrophy, i.e., they are larger, more regularly 
shaped  and  have highly  organized  actin  fibers as  shown by the 
brightly stained bands, c shows cells treated with phenylephrine in 
the presence of 10 mM 2AP. These cells also have highly organized 
actin visible as bright bands but are not as large or as regularly 
shaped as the phenylephrine-treated  ceils in b. Bar, 20/~m. 
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cells treated with phenylephrine. These cells have increased 
in size and show highly organized actin visible as discrete 
fluorescent bands. Panel c shows cells treated with both 2AP 
and phenylephrine. Clearly, these cells also have organized 
actin, however we note that they seem to be smaller than the 
phenylephrine-treated cells and often have a  spindly shape 
that is unlike the normal, hypertrophied cells. Cells treated 
with phenylephrine and 6TG also showed distinct actin or- 
ganization (data not shown).  These data therefore suggest 
that at least one of the morphological effects associated with 
hypertrophy (actin organization) does not require MAP ki- 
nase activity or any other activity which is also inhibited by 
2AP. 
To  confirm  this  result,  an  experiment  was  performed 
where the mutant Erkl expression plasmid was transfected 
or injected into cells along with a constitutively active RSV- 
luciferase molecule which was used to identify cells contain- 
ing the expression plasmids (Thorburn et al.,  1993). After 
treatment with phenylephrine for 48 h, the cells were fixed 
and stained for luciferase and with FITC-conjugated phal- 
loidin. Fig. 6 shows that cells expressing the mutant kinase 
as  a  result  of either  transfection or  microinjection have 
highly organized actin again  suggesting  that  inhibition of 
MAP  kinase  activity  does  not  prevent cytoskeletal rear- 
rangement. As expected, expression of the wild-type Erkl 
protein also had no effect on phenylephrine-induced actin or- 
ganization. 
Discussion 
This work demonstrates that MAP kinase activation by phen- 
ylephrine is important for transactivation of the fos, ANF, 
and MLC-2 genes which are all activated as a result of  hyper- 
trophic stimulation. However, MAP kinase activity does not 
seem to be required for the changes in contractile protein or- 
ganization which also occurs as a  result of phenylephrine 
treatment. 
Agonists which induce the hypertrophic response in neo- 
natal  ventricular  myocytes activate  MAP  kinase  activity 
(Fig.  1,  Bogoyevitch et al.,  1993;  Sadoshima and Izumo, 
1993a; Yamazaki et al., 1993; Bogoyevitch  et al., 1994). We 
Figure 6.  Transfected or mi- 
croinjected  K71RErkl does 
not  prevent  phenylephrine- 
induced organization of actin. 
Cells on chamber slides were 
transfected with pCEP4K71R- 
Erld  plus  RSV-luciferase (a 
and b), or, as a control, with 
the wild-type pCEP4Erkl plus 
RSV-luciferase (c and d). Al- 
ternatively cells were micro- 
injected  with  pCEP4K71R- 
Erkl  plus  RSV-luciferase (e 
and f).  After treatment with 
phenylephrine  for 48  h,  the 
cells  were  fixed and  stained 
with an antibody against lucif- 
erase to identify  the tmnsfected 
or injected  cells and with FITC- 
phalloidin to show actin, a, c, 
and e show luciferase staining 
which is in a speckled pattern 
as a result of luciferase trans- 
port into peroxisomes while b, 
d, andfshow actin staining of 
the same fields. Note that all 
the cells including those that 
were  transfected  or  injected 
(arrowed) have highly orga- 
nized actin indicating that ex- 
pression  of the  mutant  Erkl 
does not prevent actin organ- 
ization. Bars, 20/zm. 
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reducing MAP kinase activity in the cell by either treating 
the cells with pharmacological agents which inhibit MAP ki- 
nases or by expressing a dominant inhibitor of the 44-kD 
MAP kinase, Erkl. Inhibition of MAP kinases by either of 
these approaches prevents phenylephrine-induced activation 
of gene expression (Figs. 2,  3, and 4).  Using either these 
pharmacological inhibitors  or  similar  dominant negative 
mutants, a requirement for MAP kinase activation has also 
been demonstrated for NGF-induced differentiation of PC12 
cells  (Qiu  and Green,  1992),  proliferation of fibroblasts 
(Pages et al., 1993), and activation of  AP1 transcriptional ac- 
tivity (Frost et al., 1994;  Pages et al., 1993).  We note that 
expression of  the mutant Erkl molecule is able to completely 
block  phenylephrine-induced transactivation of the  ANF 
promoter.  We do not know whether this means that only 
Erkl is important for this phenotype or whether the one mu- 
tant inhibits more than one of the MAP kinases. A similar 
effect was found for inhibition of fibroblast proliferation and 
growth factor-induced AP1 activity using a different Erkl in- 
hibitor (Pages et al., 1993). We cannot exclude the possibil- 
ity that the dominant negative Erkl molecule also inhibits 
other kinases which are similar to the MAP kinases, and it 
is therefore possible that some of the effects which we ob- 
served may be due to inhibition of these molecules. 
The experiments presented here also show that not all 
phenotypes associated with a particular signaling pathway 
need necessarily require normal levels of MAP kinase activ- 
ity since inhibition of MAP kinases by either 2AP treatment 
or  expression  of the  KTIR mutant does  not prevent  the 
changes in actin organization which are associated with the 
hypertrophic response (Figs. 5 and 6). It should be noted that 
it is unlikely that inhibition of MAP kinase activity by either 
approach was 100%  effective. It is therefore possible that a 
low level of MAP kinase activity does play a role in actin or- 
ganization. 
Despite this caveat, the simplest explanation of our data 
is that the diverse effects associated with cardiac cell hy- 
pertrophy  (i.e.,  both  gene expression  and morphological 
changes) arise from signal transduction pathways which di- 
verge upstream of the MAP kinases. Previously, we showed 
that activated Ras protein could induce both ANF expression 
and contractile protein organization (Thorburn et al., 1993) 
suggesting that the divergence in the signaling pathway lead- 
ing to both types of  phenotype occurs between Ras and MAP 
kinase. This might be achieved by using different Ras effector 
molecules for each effect.  An attractive idea would be that 
the Raf-1 kinase is the Ras effector which leads to MAP ki- 
nase activation (Howe et al.,  1992;  Kyriakis et al.,  1992; 
Moodie et al., 1993) and subsequent gene expression changes 
while another effector molecule such as p120 ~^P leads to 
morphological changes perhaps via p190 and the Rho protein 
(McGlade et al.,  1993).  Recently, we have found that an 
estradiol-inducible Raf-1 molecule can induce MAP kinase 
activation and cause  expression  from the fos,  ANF,  and 
MLC-2 promoters in the absence of any other stimuli but is 
not able  to  induce actin organization (Thorburn,  J.,  M. 
McMahon and A. Thorburn, manuscript submitted for pub- 
lication) supporting this hypothesis. 
Ras has been shown to be involved in other heterotrimeric 
G protein-coupled receptor signaling pathways (Kupperman 
et al., 1993; LaMorte et al., 1993; van Corven et al., 1993) 
including MAP kinase activation by lysophosphatidic acid 
(Cook et al., 1993; Howe and Marshall, 1993) and the ace- 
tylcholine muscarinic m2 receptor (Winitz et al., 1993), and 
so the involvement of the Ras-Raf-MEK-MAP kinase signal- 
ing pathway in G protein-coupled systems may be common. 
However, Ras-independent pathways exist which can lead to 
MAP kinase activation (Lange-Carter et al., 1993; Burger- 
ing et al., 1993),  and these pathways may be especially im- 
portant for heterotrimeric G-protein coupled systems. It is 
likely that a  complicated network of interrelated signaling 
pathways regulate cellular responses like growth and hyper- 
trophy and it will be necessary to study each putative signal- 
ing molecule independently to uncover the relationships be- 
tween the pathways involved.  The  strategies used in this 
study are  applicable to  other  signaling molecules  and it 
should be possible to use this approach to define the various 
relationships between different signaling pathways. It is not 
surprising that signal transduction pathways diverge to cause 
different phenotypes, however the clear separation of the re- 
sponses associated with cardiac myocyte hypertrophy may 
make this a particularly useful experimental system in which 
to analyze such complicated pathways. 
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